quinolinic acid has been researched along with Idiopathic Parkinson Disease in 21 studies
Quinolinic Acid: A metabolite of tryptophan with a possible role in neurodegenerative disorders. Elevated CSF levels of quinolinic acid are correlated with the severity of neuropsychological deficits in patients who have AIDS.
pyridinedicarboxylic acid : Any member of the class of pyridines carrying two carboxy groups.
quinolinic acid : A pyridinedicarboxylic acid that is pyridine substituted by carboxy groups at positions 2 and 3. It is a metabolite of tryptophan.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Boosting KYNA levels, through interference with the KP enzymes or through application of prodrugs/analogs with high bioavailability and potency, is a promising clinical approach." | 2.82 | Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword? ( Ostapiuk, A; Urbanska, EM, 2022) |
| "L-kynurenine is a central compound of this pathway since it can change to the neuroprotective agent kynurenic acid or to the neurotoxic agent quinolinic acid." | 2.43 | Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies. ( Németh, H; Toldi, J; Vécsei, L, 2006) |
| "Adenosine A2 receptors were labeled and visualized by autoradiography in tissue sections of the human brain using the A2-selective agonist ligand [3H](2-p-(2-carboxyethyl)phenylamino)-5'-N-carboxamidoadenosine (CGS 21680)." | 1.28 | Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease. ( Martinez-Mir, MI; Palacios, JM; Probst, A, 1991) |
| "These neurons degenerate in Alzheimer's disease, and there is a corresponding deficiency of cortical choline acetyltransferase activity." | 1.27 | Galanin-like immunoreactivity is unchanged in Alzheimer's disease and Parkinson's disease dementia cerebral cortex. ( Beal, MF; Chattha, GK; Clevens, RA; Gabriel, SM; MacGarvey, UM; Mazurek, MF, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.76) | 18.7374 |
| 1990's | 6 (28.57) | 18.2507 |
| 2000's | 7 (33.33) | 29.6817 |
| 2010's | 5 (23.81) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Ostapiuk, A | 1 |
| Urbanska, EM | 1 |
| Qin, W | 1 |
| Shi, Y | 1 |
| Chen, W | 1 |
| Jia, X | 1 |
| Asakawa, T | 1 |
| Thirtamara-Rajamani, K | 1 |
| Li, P | 1 |
| Escobar Galvis, ML | 1 |
| Labrie, V | 1 |
| Brundin, P | 2 |
| Brundin, L | 1 |
| Robertson, DS | 1 |
| Yoon, HH | 1 |
| Kim, YH | 1 |
| Shin, ES | 1 |
| Jeon, SR | 1 |
| Kaindlstorfer, C | 1 |
| García, J | 1 |
| Winkler, C | 1 |
| Wenning, GK | 1 |
| Nikkhah, G | 1 |
| Döbrössy, MD | 1 |
| Tan, L | 2 |
| Yu, JT | 1 |
| Olds, ME | 2 |
| Jacques, DB | 2 |
| Kpoyov, O | 1 |
| Kopyov, O | 1 |
| Németh, H | 1 |
| Toldi, J | 1 |
| Vécsei, L | 1 |
| Oo, TF | 2 |
| Henchcliffe, C | 1 |
| James, D | 1 |
| Burke, RE | 2 |
| Lonser, RR | 1 |
| Corthésy, ME | 1 |
| Morrison, PF | 1 |
| Gogate, N | 1 |
| Oldfield, EH | 1 |
| Kholodilov, NG | 1 |
| Neystat, M | 1 |
| Lo, SE | 1 |
| Larsen, KE | 1 |
| Sulzer, D | 1 |
| Emgård, M | 1 |
| Karlsson, J | 1 |
| Hansson, O | 1 |
| Levivier, M | 1 |
| Donaldson, D | 1 |
| Ravikumar, A | 1 |
| Deepadevi, KV | 1 |
| Arun, P | 1 |
| Manojkumar, V | 1 |
| Kurup, PA | 1 |
| Stone, TW | 1 |
| Wu, HQ | 1 |
| Rassoulpour, A | 1 |
| Schwarcz, R | 1 |
| Taylor, R | 1 |
| Martinez-Mir, MI | 1 |
| Probst, A | 1 |
| Palacios, JM | 1 |
| Beal, MF | 1 |
| Clevens, RA | 1 |
| Chattha, GK | 1 |
| MacGarvey, UM | 1 |
| Mazurek, MF | 1 |
| Gabriel, SM | 1 |
6 reviews available for quinolinic acid and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Topics: Alzheimer Disease; Animals; Brain; Excitatory Amino Acid Antagonists; Humans; Huntington Disease; Ky | 2022 |
Can kynurenine pathway be considered as a next-generation therapeutic target for Parkinson's disease? An update information.
Topics: 3-Hydroxyanthranilic Acid; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Levodopa; Parki | 2022 |
Is the Enzyme ACMSD a Novel Therapeutic Target in Parkinson's Disease?
Topics: Animals; Brain; Carboxy-Lyases; Humans; Inflammation; Mutation; Parkinson Disease; Quinolinic Acid | 2017 |
The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Topics: Aging; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Enzyme Inhibitors; Humans; Hunting | 2012 |
Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies.
Topics: Animals; Humans; Kynurenine; Neurodegenerative Diseases; Parkinson Disease; Quinolinic Acid; Recepto | 2006 |
Kynurenic acid antagonists and kynurenine pathway inhibitors.
Topics: Brain Ischemia; Epilepsy; Excitatory Amino Acid Antagonists; Humans; Kynurenic Acid; Kynurenine; Neu | 2001 |
15 other studies available for quinolinic acid and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Proposed biochemistry of Parkinson's and Alzheimer's diseases.
Topics: Aldehydes; Alzheimer Disease; Aspartic Acid; Betaine; Brain; Disease Progression; Humans; Kynurenine | 2017 |
A rat model of striatonigral degeneration generated by simultaneous injection of 6-hydroxydopamine into the medial forebrain bundle and quinolinic acid into the striatum.
Topics: Animals; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Mem | 2014 |
Behavioral and histological analysis of a partial double-lesion model of parkinson-variant multiple system atrophy.
Topics: Animals; Apomorphine; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Dopami | 2012 |
Behavioral/neurophysiological investigation of effects of combining a quinolinic acid entopeduncular lesion with a fetal mesencephalic tissue transplant in striatum of the 6-OHDA hemilesioned rat.
Topics: Amphetamine; Animals; Apomorphine; Brain Diseases; Brain Tissue Transplantation; Corpus Striatum; Do | 2003 |
Behavioral and anatomical effects of quinolinic acid in the striatum of the hemiparkinsonian rat.
Topics: Adrenergic Agents; Amphetamine; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; | 2005 |
Expression of c-fos, c-jun, and c-jun N-terminal kinase (JNK) in a developmental model of induced apoptotic death in neurons of the substantia nigra.
Topics: Animals; Apoptosis; Dopamine; Female; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase 4; Mi | 1999 |
Convection-enhanced selective excitotoxic ablation of the neurons of the globus pallidus internus for treatment of parkinsonism in nonhuman primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Albumins; Animals; Antiparkinson Agents; Disease Model | 1999 |
Increased expression of rat synuclein in the substantia nigra pars compacta identified by mRNA differential display in a model of developmental target injury.
Topics: alpha-Synuclein; Amino Acid Sequence; Animals; Apoptosis; Base Sequence; Blotting, Northern; Blottin | 1999 |
Patterns of cell death and dopaminergic neuron survival in intrastriatal nigral grafts.
Topics: Animals; Apoptosis; Biomarkers; Brain Tissue Transplantation; Cell Survival; Corpus Striatum; Dopami | 1999 |
Metabolic changes after injection of quinolinic acid or 6-hydroxydopamine in the rat striatum: a time-course study using cytochrome oxidase and glycogene phosphorylase a histochemistry.
Topics: Animals; Autoradiography; Benzazepines; Biomarkers; Corpus Striatum; Disease Models, Animal; Dopamin | 2000 |
Tryptophan and tyrosine catabolic pattern in neuropsychiatric disorders.
Topics: Adult; Biogenic Monoamines; Brain Diseases; Brain Neoplasms; Digoxin; Epilepsy, Generalized; Erythro | 2000 |
Effect of systemic L-DOPA administration on extracellular kynurenate levels in the rat striatum.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Astrocytes; Dopamine; Dose-Response Relationship, | 2002 |
A lot of "excitement' about neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Alzheimer Disease; Animals; Dizocilpine Maleate | 1991 |
Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease.
Topics: Adenosine; Aged; Aged, 80 and over; Animals; Basal Ganglia; Corpus Striatum; Female; Guinea Pigs; Hu | 1991 |
Galanin-like immunoreactivity is unchanged in Alzheimer's disease and Parkinson's disease dementia cerebral cortex.
Topics: Aged; Alzheimer Disease; Animals; Cerebral Cortex; Choline O-Acetyltransferase; Chromatography, High | 1988 |